Skip to main content

Deal Capsule - April 2017

Page 1

Deal Capsule Transactions in Chemicals & Pharmaceuticals April 2017

M&A in Life Sciences continued apace, particularly with strong interest for biotech assets in oncology. Consolidation in the paints and coatings sector drives high levels of Chemicals M&A.

VIR LAKSHMAN | HEAD OF CHEMICALS & PHARMACEUTICALS, KPMG IN GERMANY

HIGHLIGHTS

FIGURE 1: TRENDS IN PHARMACEUTICALS M&A

—— M&A continues to be brisk with the number of completed deals in both sectors remaining at a high level. One pharmaceutical deal completed in Q1 2017 broke the $10 billion mark. Chemicals saw a deal above $20 billion being announced. —— Big pharma players continue to acquire biotechs, particularly in the oncology area. Venture Capital is also increasing investments in biotech assets. —— Transactions in Chemicals focused on paints and coatings and plastics. —— US and China remain the most active countries. Japanese companies were more active and participated in some large deals. —— KPMG’s Deal Thermometer indicates that the environment for M&A activity will remain moderately strong in both pharmaceuticals and chemicals.

755

722

100

79

2011

2012

797

697

821

778 204

69

170

298

2013

2014

2015

Deal Value in $ bn.

180

36

28

185

2016 Q1 2016 Q1 2017 Number of Completed Deals

Sources: Thomson One, KPMG Analysis

FIGURE 2: TRENDS IN CHEMICALS M&A

883

872

83

34

2011

2012

829

776

806

53

60

76

2013

2014

2015

Deal Value in $ bn.

774

72

181

183

14

10

2016 Q1 2016 Q1 2017 Number of Completed Deals

Sources: Thomson One, KPMG Analysis

DEAL THERMOMETER Q1 2017 KPMG’s Deal Thermometer signals the environment for M&A deals in chemicals and pharmaceuticals. It combines the appetite for deals (changes in forward P/E ratios) with the capacity to fund deals (changes in Net Debt/ EBITDA multiples). ‘Hot’ signifies an environment conducive to deal-making. HOT

PHARMACEUTICALS DEAL APPETITE (Forward P/E ratio)

DEAL CAPACITY (Net debt/EBITDA)

CHEMICALS DEAL APPETITE (Forward P/E ratio)

MODERATE

15.1

14.9

14.3

16.0

DEAL CAPACITY (Net debt/EBITDA)

1.3x 0.9x

0.8x 0.5x 37%

6% 31 Mar 2016

31 Mar 2017

31 Mar 2017

Sources: Capital IQ, KPMG Analysis

4% 31 Mar 2018

COOL

31 Mar 2016

31% 31 Mar 2017

31 Mar 2017

Sources: Capital IQ, KPMG Analysis

31 Mar 2018


Turn static files into dynamic content formats.

Create a flipbook